Cargando…

Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

Genetically engineered mouse models of cancer can be used to filter genome‐wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurmeister, Sarah, Ramos‐Montoya, Antonio, Sandi, Chiranjeevi, Pértega‐Gomes, Nelma, Wadhwa, Karan, Lamb, Alastair D, Dunning, Mark J, Attig, Jan, Carroll, Jason S, Fryer, Lee GD, Felisbino, Sérgio L, Neal, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840539/
https://www.ncbi.nlm.nih.gov/pubmed/29437778
http://dx.doi.org/10.15252/emmm.201708274
_version_ 1783304598070493184
author Jurmeister, Sarah
Ramos‐Montoya, Antonio
Sandi, Chiranjeevi
Pértega‐Gomes, Nelma
Wadhwa, Karan
Lamb, Alastair D
Dunning, Mark J
Attig, Jan
Carroll, Jason S
Fryer, Lee GD
Felisbino, Sérgio L
Neal, David E
author_facet Jurmeister, Sarah
Ramos‐Montoya, Antonio
Sandi, Chiranjeevi
Pértega‐Gomes, Nelma
Wadhwa, Karan
Lamb, Alastair D
Dunning, Mark J
Attig, Jan
Carroll, Jason S
Fryer, Lee GD
Felisbino, Sérgio L
Neal, David E
author_sort Jurmeister, Sarah
collection PubMed
description Genetically engineered mouse models of cancer can be used to filter genome‐wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumours arising in two established mouse models of prostate cancer, PB‐Cre/Pten(loxP/loxP) and p53(loxP/lox) (P)Rb(loxP/loxP), and integrated this with published human prostate cancer expression data to pinpoint cancer‐associated gene expression changes that are conserved between the two species. To identify potential therapeutic targets, we then filtered this information for genes that are either known or predicted to be druggable. Using this approach, we revealed a functional role for the kinase MELK as a driver and potential therapeutic target in prostate cancer. We found that MELK expression was required for cell survival, affected the expression of genes associated with prostate cancer progression and was associated with biochemical recurrence.
format Online
Article
Text
id pubmed-5840539
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58405392018-03-14 Identification of potential therapeutic targets in prostate cancer through a cross‐species approach Jurmeister, Sarah Ramos‐Montoya, Antonio Sandi, Chiranjeevi Pértega‐Gomes, Nelma Wadhwa, Karan Lamb, Alastair D Dunning, Mark J Attig, Jan Carroll, Jason S Fryer, Lee GD Felisbino, Sérgio L Neal, David E EMBO Mol Med Research Articles Genetically engineered mouse models of cancer can be used to filter genome‐wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumours arising in two established mouse models of prostate cancer, PB‐Cre/Pten(loxP/loxP) and p53(loxP/lox) (P)Rb(loxP/loxP), and integrated this with published human prostate cancer expression data to pinpoint cancer‐associated gene expression changes that are conserved between the two species. To identify potential therapeutic targets, we then filtered this information for genes that are either known or predicted to be druggable. Using this approach, we revealed a functional role for the kinase MELK as a driver and potential therapeutic target in prostate cancer. We found that MELK expression was required for cell survival, affected the expression of genes associated with prostate cancer progression and was associated with biochemical recurrence. John Wiley and Sons Inc. 2018-02-05 2018-03 /pmc/articles/PMC5840539/ /pubmed/29437778 http://dx.doi.org/10.15252/emmm.201708274 Text en © 2018 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Jurmeister, Sarah
Ramos‐Montoya, Antonio
Sandi, Chiranjeevi
Pértega‐Gomes, Nelma
Wadhwa, Karan
Lamb, Alastair D
Dunning, Mark J
Attig, Jan
Carroll, Jason S
Fryer, Lee GD
Felisbino, Sérgio L
Neal, David E
Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
title Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
title_full Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
title_fullStr Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
title_full_unstemmed Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
title_short Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
title_sort identification of potential therapeutic targets in prostate cancer through a cross‐species approach
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840539/
https://www.ncbi.nlm.nih.gov/pubmed/29437778
http://dx.doi.org/10.15252/emmm.201708274
work_keys_str_mv AT jurmeistersarah identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT ramosmontoyaantonio identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT sandichiranjeevi identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT pertegagomesnelma identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT wadhwakaran identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT lambalastaird identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT dunningmarkj identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT attigjan identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT carrolljasons identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT fryerleegd identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT felisbinosergiol identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach
AT nealdavide identificationofpotentialtherapeutictargetsinprostatecancerthroughacrossspeciesapproach